Vel is a blood group antigen found on the surface of red blood cells in the vast majority of people. It was discovered in 1952 after a patient named Mrs. Vel developed antibodies against transfused blood, revealing a previously unknown marker. For decades, the molecular basis of Vel remained a mystery, but in 2013 two research teams independently identified the gene responsible: SMIM1, a small protein embedded in the red blood cell membrane. Vel matters most in blood transfusion, where a mismatch can trigger severe, potentially life-threatening reactions.
The Vel Antigen and How It Works
The Vel antigen is produced by the SMIM1 gene, which codes for a tiny protein only 78 amino acids long. This protein sits in the red blood cell membrane with a large portion extending outside the cell. It naturally pairs up with a copy of itself, forming a two-unit structure (a dimer) held together by chemical bonds. The paired form, weighing roughly 18 to 20 kilodaltons, is what the immune system recognizes as the Vel antigen.
SMIM1 is most active in the bone marrow, where red blood cells are produced, and in early red blood cell precursor cells. It also shows some activity in salivary glands and the testes, though its function outside of blood cells isn’t well understood. Animal studies in zebrafish suggest the protein plays a role in red blood cell development: when researchers suppressed the gene, the fish produced fewer mature red blood cells. In humans, certain genetic variants that lower SMIM1 activity are linked to lower hemoglobin concentration inside red blood cells and subtle changes in red blood cell size and count.
What Makes Someone Vel-Negative
Almost everyone is Vel-positive, meaning their red blood cells carry the Vel antigen. The Vel-negative phenotype is rare, occurring in roughly 1 in 4,000 people of European descent. It results from a specific 17-base-pair deletion in the SMIM1 gene. When a person inherits this deletion from both parents (homozygous), the gene can no longer produce a functional protein, and no Vel antigen appears on their red blood cells.
People who carry just one copy of the deletion (heterozygous) still produce the Vel antigen, but at reduced levels. This creates a “weak Vel” expression that follows a dosage pattern: two working copies of the gene produce full expression, one working copy produces partial expression, and zero working copies produce none. This gradient can make laboratory testing tricky, since weakly Vel-positive samples sometimes give ambiguous results with standard antibody-based tests.
Why Vel Status Matters for Transfusion
The clinical significance of the Vel blood group comes down to one serious risk: antibodies against Vel can cause severe hemolytic transfusion reactions. When a Vel-negative person is exposed to Vel-positive blood through a transfusion, their immune system may produce anti-Vel antibodies. If they receive Vel-positive blood again, those antibodies attack and destroy the transfused red blood cells, potentially causing kidney failure, shock, and death.
This is particularly dangerous because Vel-negative individuals are so uncommon. Blood banks may not routinely screen for Vel status, and finding compatible Vel-negative donors on short notice can be extremely difficult. For Vel-negative patients who have already developed antibodies, every future transfusion requires careful crossmatching or access to a rare donor registry.
Testing and Identification
Traditionally, Vel status was determined using serological methods, essentially mixing a patient’s blood with known anti-Vel antibodies and watching for a reaction. The challenge was that anti-Vel antibodies from different donors varied in strength and reliability, making consistent testing difficult. Weak Vel expression in carriers of a single gene deletion added another layer of complexity.
The 2013 discovery of the SMIM1 gene and its 17-base-pair deletion opened the door to genetic testing. DNA-based methods can now definitively identify whether someone carries zero, one, or two copies of the deletion, removing the ambiguity of antibody-based approaches. This is especially useful for screening blood donors in large-scale programs, where identifying rare Vel-negative individuals can build a registry of compatible donors for those who need them.
Vel in the Larger Blood Group Picture
Most people are familiar with the ABO and Rh blood group systems, but the International Society of Blood Transfusion recognizes over 40 blood group systems, and Vel is one of them. While ABO and Rh mismatches account for the most common transfusion complications, rare blood group antigens like Vel pose unique challenges precisely because they are so infrequently encountered. A patient may go through multiple transfusions without issue, only to develop anti-Vel antibodies seemingly out of nowhere.
For the average person, Vel status will never come up. But for the small number of Vel-negative individuals, especially those who need repeated transfusions due to chronic illness, surgery, or trauma, knowing their Vel status can be lifesaving. If you’ve ever been told you have a rare blood type or experienced an unexplained transfusion reaction, Vel-negative status is one of the possibilities a hematologist might investigate.